That would be great ds but in order to have a good 2014 they simply have to do deals and restore market faith. The rest is nice, but meaningless without commercial outcomes.
They can have the best tech in the world, the best lab team, the best board, the greatest potential, etc... but if they can't make money off it then the share market will not reward them. This piece of the PYC puzzle is not rocket science.
As has been suggested, the Janssen deal could well prove to be a catalyst - Jan/Feb..? If this comes through perhaps it will validate the science and other deals may follow?
All very speculative and unfortunately not a lot of info to go on when considering the entitlement offer...
Anyone care to share their thoughts on whether putting more money into PYC would be a good or bad thing...?
molecular partners, page-3
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.005(2.44%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $958.2K | 4.847M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 334614 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 379756 | 5 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |